Alexandra P. Ikeguchi, MD

Peer-Reviewed Articles

1. Patel SP, Othus M, Chen Y, Wright GP, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA, Truong TG, Eisenstein JL, Chandra S, Sosman JA, Kendra KL, Wu RC, Devoe CE, Deutsch GB, Hegde A, Khalil M, Mangla A, Reese AM, Ross MI, Poklepovic AS, Phan GQ, Onitilo AA, Yasar DG, Powers BC, Doolittle GC, In GK, Kokot N, Gibney GT, Atkins MB, Shaheen M, Warneke JA, Ikeguchi A, Najera JE, Chmielowski B, Crompton JG, Floyd JD, Hsueh E, Margolin KA, Chow WA, Grossmann KF, Dietrich E, Prieto VG, Lowe MC, Buchbinder EI, Kirkwood JM, Korde L, Moon J, Sharon E, Sondak VK, Ribas A. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 388(9):813-823, 2023. PMID: 36856617.
2. Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O'Rourke M, Stephenson JJ, Curti BD, Urba WJ, Brell JM, Funchain P, Kendra KL, Ikeguchi AP, Jaslowski A, Bane CL, Taylor MA, Bajaj M, Conry RM, Ellis RJ, Logan TF, Laudi N, Sosman JA, Crockett DG, Pecora AL, Okazaki IJ, Reganti S, Chandra S, Guild S, Chen HX, Streicher HZ, Wolchok JD, Ribas A, Kirkwood JM. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol 41(2):186-197, 2023. e-Pub 2022. PMID: 36166727.
3. Atkins, M. B., Lee, S. J., Chmielowski, B., Tarhini, A. A., Truong, T.-G., Moon, H. H., Davar, D., O'Rourke, M., Stephenson, J. J., Curti, B. D., Urba, W., Brell, J. M., Funchain, P., Kendra, K. L., Ikeguchi, A. P., Jaslowski, A., Bane, C. L., Taylor, M. A., Bajaj, M., Conry, R. M., Ellis, R. J., Logan, T. F., Laudi, N., Sosman, J. A., Crockett, D. G., Pecora, A. L., Okazaki, I. J., Reganti, S., Chandra, S., Guild, S., Chen, H. X., Streicher, H. Z., Wolchok, J. D., Ribas, A., Kirkwood, J. M.. Combination Targeted Therapy or Immune Checkpoint Blockade as Initial Treatment for Patients with BRAF Mutated Melanoma. Journal of Clinical Oncology, 2023. PMID: 36166727.
4. Carvajal RD, Butler MO, Shoushtari AN, Hassel JC, Ikeguchi A, Hernandez-Aya L, Nathan P, Hamid O, Piulats JM, Rioth M, Johnson DB, Luke JJ, Espinosa E, Leyvraz S, Collins L, Goodall HM, Ranade K, Holland C, Abdullah SE, Sacco JJ, Sato T. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nat Med 28(11):2364-2373, 2022. e-Pub 2022. PMID: 36229663.
5. Sato, T., Ikeguchi, AP, Nathan, P., Carvajal, R.D., Shoushtari, A.N., Gajewski, T.F., Hassel, J.C., Rioth, M., Leyvraz, S., Daniels, G.A., Hernandez-Aya, L., Johnson, D.B., Kim, K., Piulats Rodriguez, J.M., Cowey, C.L., Lockwood, S., Collins, L. K., Karakuzu, O., Sacco, J.J., Butler, M.O.. 843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma. Annals of Oncology, 2022. e-Pub 2022.
6. Carvajal, R., Butler, M., Shoushtari, A., Hassel, J., Ikeguchi, A. P., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J., Rioth, M., Johnson, D., Luke, J., Espinosa, E., Leyvraz, S., Collins, L., Goodall, H., Ranade, K., Holland, C., Abdullah, S., Sacco, J., Sato, T. Clinical and Molecular Response to Tebentafusp in Previously-Treated Patients with Metastatic Uveal Melanoma: A Phase 2 Trial. Nature Medicine, 2022.
7. Sato, T., Ikeguchi, A. P., Nathan, P., Carvajal, R.D., Shoushtari, A.N., Gajewski, T.F., Hassel, J.C., Rioth, M., Leyvraz, S., Daniels, G.A., Hernandez-Aya, L., Johnson, D.B., Kim, K., Piulats Rodriguez, J.M., Cowey, C.L., Lockwood, S., Collins, L. K., Karakuzu, O., Sacco, J.J., Butler, M.O.. Long-Term Survivors on Tebentafusp in Phase II Trial of Previously Treated Patients with Metastatic Uveal Melanoma. Annals of Oncology, 2022.
8. Garcia-Ramiu, K, Mohsin, I., Ikeguchi, A. P., Newberry, B.. An Unusual Case of Malignant Melanoma with Metastasis to the Placenta During Pregnancy. . European Journal of Case Reports in Internal Medicine, 2022.
9. Vanderwalde, A. M., Moon, J., Kendra, K., Khushalani, N. I., Collichio, F., Sosman, J. A., Ikeguchi, A. P., Victor, A. I., Truong, T.-G., Chmielowski, B., Portnoy, D. C., Wu, M. C., Grossmann, K. F., Ribas, A. : Ipilimumab Plus Nivolumab versus Ipilimumab Alone in Patients with Metastatic or Unresectable Melanoma That Did Not Respond to Anti-PD-1 Therapy. Cancer Research, 2022.
10. ImmunoTherapy of Cancer. Updated Survival of Patients with Previously Treated Metastatic Uveal Melanoma Who Received Tebentafusp. Journal for ImmunoTherapy of Cancer, 2021.
11. Shoushtari, A.N., Collins, L. K., Espinosa, E., Sethi, H., Stanhope, S., Abdullah, S., Ikeguchi, A. P., Ranade, K., Hamid, O. Response, is Associated with Overall Survival (OS) on Tebentafusp in Previously Treated Metastatic Uveal Melanoma (mUM) Patients. Annals of Oncology, 2021.
12. Carvajal, R. D., Sato, T., Butler, M. O., Sacco, J. J., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A. P., Hernandez-Aya, L. F., Rioth, M., Hamid, O., Piulats, J. M., Luke, J. J., Johnson, D. B., Leyvraz, S., Espinosa, E., Collins, L., McCully, M. L., Lockwood, S., Abdullah, S. E., Nathan, P.. Characterization of Cytokine Release Syndrome (CRS) Following Treatment with Tebentafusp in Patients (pts) with Previously Treated (2L+) Metastatic Uveal Melanoma (mUM. Journal of Clinical Oncology, 2021.
13. Sato, T., Carvajal, R. D., Sacco, J. J., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A. P., Hernandez-Aya, L. F., Nathan, P., Rioth, M., Hamid, O., Piulats, J. M., Luke, J. J., Johnson, D. B., Leyvraz, S., Espinosa, E., Abdullah, S. E., Sum, D., Lockwood, S., Mendez, P., Butler, M. O.. Characterization of Liver Function Tests (LFTs) Following Tebentafusp (tebe) in Previously Treated (2L+) Metastatic Uveal Melanoma (mUM) Patients (pts). Journal of Clinical Oncology, 2021.
14. Sacco, J.J., Carvajal, R., Butler, M.O., Shoushtari, A.N., Hassel, J.C., Ikeguchi, A. P., Hernandez-Aya, L., Nathan, P., Hamid, O., Rodriguez, J.M. P., Rioth, M., Johnson, D.B., Luke, J.J., Espinosa, E., Leyvraz, S., Goodall, H.M., Holland, C. E., Abdullah, S., Sato, T.. Multi-Center Study of the Safety and Efficacy of Tebentafusp (tebe) (IMCgp100) in Patients (pts) with Metastatic Uveal Melanoma. Annals of Oncology,, 2020.
15. Ikeguchi, AP ,Machiorlatti, M, Vesely, S. K. Disparity in Outcomes of Melanoma Adjuvant Immunotherapy by Demographic Profile. Melanoma Management, 2020. PMID: 32821375.
16. Ikeguchi A, Yang HY, Gao G, Goff SP. Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1. Oncogene 20(36):4926-34, 2001. PMID: 11526477.

Other Articles

1. Tarhini, A. a., Coleman, S. s., El Naqa, I., Sukrithan, V., Aakrosh, R., McCarter, M., Carpten, J., Colman, H., Ikeguchi, A. P., Puzanov, I., Arnold, S., Churchman, M. L., Hwu, P., Conejo-Garcia, J. R., Dalton, W. S., Weiner, G. J., Tan, A. C. Systematic Evaluation of Published Predictive Gene Expression Signatures in Pan-Cancer Patient Cohorts Treated with Immune Checkpoint Inhibitors in a Real-World Setting, 2022.
2. Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J. F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., Joshua, A. M., Sacco, J. J., Shoushtari, A. N., Orloff, M., Piulats, J. M., Milhem, M., Salama AKS, Curti, B., Demidov, L., Gastaud, L., Mauch, C., Yushak, M., Carvajal, R. D., Hamid, O., Abdullah, S. E., Holland, C. E., Goodall, H., Piperno-Neumann, S., Ikeguchi, A. P . Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma, 2021. PMID: 34551229.

Abstracts

1. Ari VanderWalde, Shay L. Bellasea, Kari L. Kendra, Nikhil I. Khushalani, Katie M. Campbell, Philip O. Scumpia, Lawrence F. Kuklinski, Frances Collichio, Jeffrey A. Sosman, Alexandra Ikeguchi, Adrienne I. Victor, Thach-Giao Truong, Bartosz Chmielowski, David C. Portnoy, Yuanbin Chen, Kim Margolin, Charles Bane, Constantin A. Dasanu, Douglas B. Johnson, Zeynep Eroglu, Sunandana Chandra, Egmidio Medina, Cynthia R. Gonzalez, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Ivan Perez Garcilazo, Elad Sharon, Siwen Hu-Lieskovan, Sapna P. Patel, Kenneth F. Grossmann, James Moon, Michael C. Wu & Antoni Ribas Show fewer authors. Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nature Medicine, 2023. e-Pub 2023.
2. Diwakar Davar, Alexandra Ikeguchi, Elizabeth Iannotti Buchbinder, Alexander Noor Shoushtari, Rino S. Seedor, Eric Bernicker, Sarah A. Weiss, Gregory A. Daniels, Timothy J. Panella, Hannah Frances Ryan, Howard Goodall, Ryan J. Sullivan. A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM), 2023. e-Pub 2023.
3. Joseph J. Sacco; Richard D. Carvajal; Marcus O. Butler; Alexander N. Shoushtari; Jessica C. Hassel; Alexandra Ikeguchi; Leonel Hernandez-Aya; Paul Nathan; Omid Hamid; Josep M. Piulats; Matthew Rioth; Douglas B. Johnson; Jason J. Luke; Erique Espinosa; Serge Leyvraz; Laura Collins; Chris Holland; Michelle L. McCully; Takami Sato. Abstract CT223: Long-term survival follow-up of tebentafusp in previously treated metastatic uveal melanoma (mUM). Cancer Res, 2023.
4. Kari Kendra; Shay Bellasea; Zeynep Eroglu; Siwen Hu-Lieskovan; Katie M. Campbell; William Carson; David Wada; Jose A. Plaza; Jeffrey Sosman; Gino K. IN; Alexandra Ikeguchi; John Hyngstrom; Andres Brohl; Nikhil I. Khushalani; Joseph Markowitz; George Negrea; Samer Kasbari; Gary C. Doolittle; Umang Swami; Toni Roberts; Sapna P. Patel; Elad Sharon; James Moon; Michael C. Wu; Antoni Ribas. Abstract CT009: S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma. Cancer Res, 2023.
5. Saghand, P. G., El Naqa, I., Tan, A. C., Xie, M., Dai, D., Chen, J. L., Ratan, A., McCarter, M., Carpten, J. D., Shah, H., Ikeguchi, A. P., Tripathi, A., Puzanov, I., Arnold, S. M., Churchman, M. L., Hwu, P., Conejo-Garcia, J., Dalton, W. S., Weiner, G. J., Tarhini, A. A.. A Deep Learning Approach Utilizing Clinical and Molecular Data for Identifying Prognostic Biomarkers in Patients Treated with Immune Checkpoint Inhibitors: An ORIEN Pan-cancer Study. Journal of Clinical Oncology, 2022.
6. G. K., Ikeguchi, A. P., Hyngstrom, J. R., Brohl, A. S., Chmielowski, B., Khushalani, N. I., Markowitz, J., Monroe, M., Grossmann, K. F., Sondak, V. K., Sharon, E., Wu, M., Ribas, A.. Neoadjuvant PD-1 Blockade in Patients with Resectable Desmoplastic Melanoma (. Journal of Clinical Oncology, 2022.
7. Tarhini, A. A., Tan, A. C., Xie, M., El Naqa, I., Saghand, P. G., Dai, D., Chen, J. L., Ratan, A., McCarter, M., Carpten, J. D., Colman, H., Ikeguchi, A. P., Tripathi, A., Puzanov, I., Arnold, S. M., Churchman, M. L., Hwu, P., Conejo-Garcia, J., Dalton, W. S., Weiner, G. J. Predictors of Immunotherapeutic Benefits in Patients with Advanced Melanoma and Other Malignancies Treated with Immune Checkpoint Inhibitors Utilizing ORIEN “Real-world” Data. Journal of Clinical Oncology, 2022.
8. Ikeguchi, A. P., Sacco, J. J., Luke, J. J., Evans, T.R. J., Curti, B. D., Kim, K. B., Abdullah, S. E., Watkins, C., Karakuzu, O., Nathan, P. D. Analysis of the Effect of Systemic Corticosteroids on Survival from Tebentafusp in a Phase 3 Trial of Metastatic Uveal Melanoma. Journal of Clinical Oncology, 2022.
9. Shikdar, S.*, Day, S., Ikeguchi, A. P., Ying, Y.. Comparing Overall Survival of Patients with Metastatic Uveal Melanoma by Sequence of Tebentafusp versus Combination Immune Checkpoint Inhibitors. Journal of Clinical Oncology, 2022.
10. Jensen, R. E., Zheng, Y., Atkins, M. B., Chmielowski, B., Tarhini, A. A., Truong, T.-G., Davar, D., O'Rourke, M. A., Curti, B. D., Brell, J. M., Kendra, K. L., Ikeguchi, A. P., Lee, S. J., Potosky, A. L., Wolchok, J. D., Ribas, A., Kirkwood, J. M., Wagner, L. I., Cella, D.. ). Early Quality of Life (QOL) and Symptom Analysis from the DREAMseq Phase III Randomized Control Trial of Combination Immunotherapy versus Targeted Therapy in Patients (pts) with BRAF-mutant Metastatic Melanoma. Journal of Clinical Oncology, 2022.
11. Spakowicz, D., Hoyd, R., Wheeler, C. E., Zakharia, Y., Dodd, R. D., Ose, J., Hardikar, S., Tarhini, A. A., Robinson, L. A., Singer, E. A., Carpten, J. D., Chan, C. H., Ikeguchi, A. P., Ulrich, C. M., McCarter, M.. Pan-Cancer Analysis of Exogenous (Microbial) Sequences in Tumor Transcriptome Data from the ORIEN Consortium and their Association with Cancer and Tumor Microenvironment. Journal of Clinical Oncology, 2022.
12. Atkins, M. B.+, Lee, S. J., Chmielowski, B., Ribas, A., Tarhini, A. A., Truong, T.-G., Davar, D., O'Rourke, M. A., Curti, D., Brell, J. M., Kendra, K. L., Ikeguchi, A. P., Wolchok, J. D., Kirkwood, J. M.. Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A Phase III Trial—ECOG-ACRIN EA613. Journal of Clinical Oncology, 2021.
13. Battiste, J., Ikeguchi, A. P., Woo, S., Sharan, S., Zhao, Y. D., Cohoon, A., Sung, S., Wright, D., Teague, A. M., Jensen, R. L., Kim, E. H., Yang, W. S., Towner, R. A.. Phase Ib Clinical Trial of OKN-007 in Recurrent Malignant Glioma. Journal of Clinical Oncology, 2020.
14. Ikeguchi, A. P., Machiorlatti, M., Vesely, S. K. ). Disparity in Outcomes of Melanoma Adjuvant Immunotherapy by Demographic Profile. 32821375, 2019. PMID: 32821375.
15. Qu, D., Weygant, N., Chandrakesan, P., Pitts, K., May, R., Asch, A. S., Ikeguchi, A. P., Houchen, C. W. Abstract 4034: DCLK1 is Upregulated in Melanoma and It Is a Novel Predictive Marker for Survival and Response. Clinical Research, 2018.
16. Qu, D., Weygant, N., Chandrakesan, P., Pitts, K., May, R., Sureban, S., Asch, A. S., Ikeguchi, A. P., Houchen, C. W.. Serum DCLK1 Levels are Elevated in Melanoma Patients and it is a Novel Predictive Marker for Survival and Response (13th ed., vol. 78). American Association of Cancer Research, 2018.